Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac ECM and Index Rebal

STAR50 Index Rebalance (Quantitative Event Study): Historical Patterns & Current Event Analysis

STAR50 Index Earning Revision (Feb): CAMBRICON, TRINA SOLAR, TRANSSION, Advanced Micro

Asia Pac IPO & Placement Research, China Biotech

DZT Research

DZT Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Index Rebalance

<ul>
<li>CSI announced four ADDs and four DELETEs for the STAR50 Jun 2026 review, effective 15 Jun 2026.</li>
<li>Our forecast hit one ADD and three DELETEs. We reviewed our HITs and MISSes.</li>
<li>The ADD miss came from one near-zone name and two fast-entry AI-chip names; stock-level positioning now drives whether to chase or fade.</li>
</ul>


CSI announced four ADDs and four DELETEs for the STAR50 Jun 2026 review, effective 15 Jun 2026.
Our forecast hit one ADD and three DELETEs. We reviewed our HITs and MISSes.
The ADD miss came from one near-zone name and two fast-entry AI-chip names; stock-level positioning now drives whether to chase or fade.


Xiamen Amoytop Biotech Co Ltd (688278 CH)

Yuanjie Semiconductor Technology (688498 CH)

STAR50 Jun 2026 Index Rebalance: Post-Announcement Positioning

Hua Hong Semiconductor

STAR50 Jun 2026 Index Rebalance: Post-Announcement Positioning